Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $16.50.

Several brokerages have recently issued reports on NMRA. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. Bank of America reduced their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday, February 14th.

Neumora Therapeutics Trading Up 3.0 %

Shares of Neumora Therapeutics stock opened at $1.71 on Friday. The stock has a market capitalization of $276.27 million, a price-to-earnings ratio of -0.91 and a beta of 2.50. Neumora Therapeutics has a twelve month low of $1.60 and a twelve month high of $21.00. The business’s 50 day simple moving average is $4.47 and its 200-day simple moving average is $9.40.

Institutional Investors Weigh In On Neumora Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $770,000. Wexford Capital LP boosted its holdings in Neumora Therapeutics by 15.7% during the fourth quarter. Wexford Capital LP now owns 252,122 shares of the company’s stock worth $2,672,000 after buying an additional 34,243 shares in the last quarter. Toronto Dominion Bank acquired a new position in Neumora Therapeutics in the fourth quarter worth approximately $364,000. Stempoint Capital LP bought a new position in shares of Neumora Therapeutics in the fourth quarter valued at $4,538,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $185,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.